Is Ajanta Pharma (AJANTPHARM) overvalued or fairly valued?

MarketChacha shows Ajanta Pharma's valuation in context — a forward P/E of about 29.7, a price-to-book of about 9.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Ajanta Pharma's revenue?

Ajanta Pharma reported revenue of ₹4,846 Cr for FY2026, with net profit of ₹947 Cr, per official filings.

What is the share price of Ajanta Pharma (AJANTPHARM)?

Ajanta Pharma last traded at ₹3,460.10 (-1.7% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Ajanta Pharma

AJANTPHARM · NSE · Pharma · India

Snapshot

TickerAJANTPHARM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees10,421

HeadquartersMumbai, India

Websitewww.ajantapharma.com

Filings tracked3

About Ajanta Pharma

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Who owns it

Promoters54.3%
Institutions24.5%
Public & other21.3%

94 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend15.7% → 19.4%

Margin has expanded by about 3.7 points — the business is getting more profitable.

Growth qualityrev 10% · PAT 16%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,598 Cr · EPS 22.50

Est. earnings growth +2.7%

Next fiscal year

Rev ₹7,109 Cr · EPS 116.59

Est. earnings growth +16.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹5,453 Cr

Net margin

19.4%

Revenue CAGR (3y)

+13.4%

Profit CAGR (3y)

+21.6%

Net profit (FY2026)

₹1,056 Cr

Ask MarketChacha about AJANTPHARM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹5,453 Cr	₹1,056 Cr	19.4%
FY2025	₹4,648 Cr	₹920 Cr	19.8%
FY2024	₹4,209 Cr	₹816 Cr	19.4%
FY2023	₹3,743 Cr	₹588 Cr	15.7%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹1,626 Cr	₹334 Cr	20.6%
Q4 FY26	₹1,422 Cr	₹267 Cr	18.8%
Q3 FY26	₹1,375 Cr	₹274 Cr	19.9%
Q2 FY26	₹1,354 Cr	₹260 Cr	19.2%
Q1 FY26	₹1,303 Cr	₹255 Cr	19.6%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Participation In Investor Conference
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
BSE8/31/2026
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....
BSE8/19/2026
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Aayush Agrawal, trustee ....
BSE7/29/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.